HG202, developed by HuidaGene Therapeutics, represents a novel approach to treating nAMD through a one-time gene-editing therapy that aims to reduce the need for frequent anti-VEGF injections, which are the current standard of care. The potential to provide long-term efficacy with a single administration could significantly alleviate the burden on healthcare systems and improve patient quality of life. The nAMD market is substantial, with existing therapies facing limitations such as treatment resistance and the need for ongoing injections. If successful, HG202 could capture a significant share of this market, particularly among patients who do not respond adequately to current therapies. The trial's outcomes will be critical in determining the asset's commercial viability and positioning against established anti-VEGF therapies.